Endocrinology and Metabolism

Original Articles

Safety and Effectiveness of Pravastatin in Korean Patients with Dyslipidemia Based on the Cardiovascular Risk Classification: Pooled Analysis of Four Observational Studies: In-Kyung Jeong, Hyuk-Sang Kwon, Dae Jung Kim, Sin Gon Kim; Received October 2, 2024 Accepted February 17, 2025 Published online April 15, 2025; DOI: https://doi.org/10.3803/EnM.2024.2200 [Epub ahead of print]

526 View
48 Download

Abstract PDF Supplementary Material PubReader ePub: Background
Despite their efficacy, statin-related adverse events (AEs) may interfere with statin treatment and contribute to negative outcomes in patients with cardiovascular diseases. In this study, we evaluated the safety and effectiveness of pravastatin in Korea.
Methods
Pooled data were collected from four multicenter prospective observational studies conducted in Korea between 2011 and 2020. Finally, 7,334 and 2,022 participants were included in the safety and effectiveness analyses, respectively. Overall safety, particularly muscle-related, incidence of new-onset diabetes mellitus (DM), changes in fasting plasma glucose and hemoglobin A1c level, achievement of target low-density lipoprotein cholesterol (LDL-C) level, and changes in LDL-C level were analyzed.
Results
At week 24, after 20 or 40 mg pravastatin treatment, safety results showed that AEs and adverse drug reactions (ADRs) were 8.7% and 1.3%, respectively, and that muscle-related AEs and ADRs were 0.5% and 0.3%, respectively, with no statistically significant difference in risk factors for statin-associated muscle symptoms. No patients developed DM during the study period. Additionally, at week 24, the achievement rates of target LDL-C levels were 87.9%, 78.4%, 57.8%, and 11.6% in low-, moderate-, high-, and very high-risk groups, respectively.
Conclusion
This study found that 20 or 40 mg pravastatin had minimal side effects and was safe for use in real-world clinical settings in Korea. Specifically, these doses effectively achieved the target LDL-C levels in patients with dyslipidemia in low-, moderate-, and high-risk groups for atherosclerotic cardiovascular disease (ASCVD). These results demonstrate that pravastatin can be safely administered continuously to patients with low-, moderate-, and high-risk ASCVD in a real-world clinical setting.

Mineral, bone & muscle
Comparison of the Effectiveness and Hypocalcemia Risk of Antiresorptive Agents in Patients with Hypercalcemia of Malignancy: Sung Hye Kong, Seung Shin Park, Jung Hee Kim, Sang Wan Kim, Se Hyun Kim, Jee Hyun Kim, Chan Soo Shin; Endocrinol Metab. 2025;40(2):289-298. Published online February 4, 2025; DOI: https://doi.org/10.3803/EnM.2024.2132

863 View
76 Download

Abstract PDF Supplementary Material PubReader ePub: Background
Hypercalcemia of malignancy (HCM), a major metabolic complication of cancer, is often managed with bisphosphonates (BP) and, increasingly, with denosumab. We aimed to compare the effectiveness and safety of denosumab with that of BP, with or without calcitonin, in treating HCM.
Methods
This retrospective cohort study was conducted at a tertiary hospital from 2017 to 2022 and included 317 patients treated for HCM. Participants were divided into three treatment groups: denosumab, intravenous (IV) BP only, and IV BP combined with calcitonin. The primary outcomes measured were changes in calcium levels and the incidence of hypocalcemia. Analysis of covariance was used to adjust for age, sex, body mass index, creatinine level, type of malignancy, and the use of furosemide and steroids.
Results
The mean participant age was 65 years, and 37.5% were female. After adjustment, both denosumab and IV BPs were found to effectively lower calcium levels. Denosumab led to a decrease of 2.0 mg/dL (−15.9%), while IV BP alone resulted in a reduction of 1.8 mg/dL (−13.9%). The largest reduction, of 2.7 mg/dL (−20.9%), occurred with IV BP and calcitonin. Both denosumab and IV BP+calcitonin yielded their lowest calcium levels within 48 hours, whereas the IV BP only group reached a nadir within 72 hours. Despite these differences in treatment effectiveness, hypocalcemia occurred significantly less frequently in the denosumab group compared to the other groups.
Conclusion
Denosumab and IV BP were similarly effective in reducing calcium levels. However, IV BP combined with calcitonin yielded a more rapid and pronounced decrease.

Review Article

Mineral, Bone & Muscle
Long-Term Efficacy and Safety of Denosumab: Insights beyond 10 Years of Use: Jeonghoon Ha, Youn-Ju Lee, Jinyoung Kim, Chaiho Jeong, Yejee Lim, Jeongmin Lee, Ki-Hyun Baek, on Behalf of the Catholic Medical Center Bone Research Group; Endocrinol Metab. 2025;40(1):47-56. Published online January 13, 2025; DOI: https://doi.org/10.3803/EnM.2024.2125

7,338 View
350 Download

Abstract PDF PubReader ePub: Osteoporosis management in post-menopausal women focuses on fracture prevention, with denosumab as a key therapeutic option. Despite its proven efficacy in reducing fracture risk and increasing bone mineral density (BMD) over 10 years, its long-term impact remains uncertain. We evaluated the literature on its efficacy and safety beyond the initial decade. Clinical trials and real-world studies confirm denosumab’s sustained efficacy, especially in lumbar spine BMD, with hip BMD stabilizing. Concerns about adverse events (AEs) like hypocalcemia and osteonecrosis of the jaw necessitate vigilant monitoring. Risks of atypical femoral fractures and malignancies also require attention, despite unclear links to treatment duration. Clinical guidelines for denosumab beyond 10 years are limited, emphasizing the need for careful monitoring. In certain scenarios, such as advanced chronic kidney disease, prolonged denosumab may be required to balance AE risks with fracture prevention benefits. Denosumab shows potential for long-term efficacy in augmenting BMD; however, monitoring for AEs is crucial to guide clinical decision-making effectively.

Original Articles

Diabetes, obesity and metabolism
Efficacy and Safety of Omarigliptin, a Novel Once-Weekly Dipeptidyl Peptidase-4 Inhibitor, in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis: A.B.M. Kamrul-Hasan, Muhammad Shah Alam, Samir Kumar Talukder, Deep Dutta, Shahjada Selim; Endocrinol Metab. 2024;39(1):109-126. Published online January 23, 2024; DOI: https://doi.org/10.3803/EnM.2023.1839

4,190 View
137 Download
14 Web of Science
13 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
No recent meta-analysis has holistically analyzed and summarized the efficacy and safety of omarigliptin in type 2 diabetes mellitus (T2DM). We conducted a meta-analysis to address this knowledge gap.
Methods
Electronic databases were searched to identify randomized controlled trials (RCTs) that included patients with T2DM who received omarigliptin in the intervention arm. The control arm consisted of either a placebo (passive control group [PCG]) or an active comparator (active control group [ACG]). The primary outcome assessed was changes in hemoglobin A1c (HbA1c), while secondary outcomes included variations in glucose levels, achievement of glycemic targets, adverse events (AEs), and hypoglycemic events.
Results
From 332 initially screened articles, data from 16 RCTs involving 8,804 subjects were analyzed. Omarigliptin demonstrated superiority over placebo in reducing HbA1c levels (mean difference, –0.58%; 95% confidence interval, –0.75 to –0.40; P<0.00001; I²=91%). Additionally, omarigliptin outperformed placebo in lowering fasting plasma glucose, 2-hour postprandial glucose, and in the percentage of participants achieving HbA1c levels below 7.0% and 6.5%. The glycemic efficacy of omarigliptin was similar to that of the ACG across all measures. Although the omarigliptin group experienced a higher incidence of hypoglycemic events compared to the PCG, the overall AEs, serious AEs, hypoglycemia, and severe hypoglycemia were comparable between the omarigliptin and control groups (PCG and ACG).
Conclusion
Omarigliptin has a favorable glycemic efficacy and safety profile for managing T2DM.

Citations

Citations to this article as recorded by

Once-Weekly Tirzepatide Versus Once-Daily Basal Insulin in Managing Type 2 Diabetes Inadequately Controlled With Oral anti-Hyperglycemic Drugs: A Systematic Review and Meta-Analysis
A.B.M. Kamrul-Hasan, Shahjada Selim, Faria Afsana, Lakshmi Nagendra, Rezwana Ahmed, Deep Dutta
Endocrine Practice.2025; 31(3): 315. CrossRef
Renal effects and safety of tirzepatide in subjects with and without diabetes: A systematic review and meta-analysis
A B M Kamrul-Hasan, Shinjan Patra, Deep Dutta, Lakshmi Nagendra, AFM Muntahi-Reza, Sanja Borozan, Joseph M Pappachan
World Journal of Diabetes.2025;[Epub] CrossRef
Tirzepatide and Cancer Risk in Individuals with and without Diabetes: A Systematic Review and Meta-Analysis
A.B.M. Kamrul-Hasan, Muhammad Shah Alam, Deep Dutta, Thanikai Sasikanth, Fatema Tuz Zahura Aalpona, Lakshmi Nagendra
Endocrinology and Metabolism.2025; 40(1): 112. CrossRef
Reasons for discontinuing tirzepatide in randomized controlled trials: A systematic review and meta-analysis
Abul Bashar Mohammad Kamrul-Hasan, Joseph M Pappachan, Deep Dutta, Lakshmi Nagendra, Mohammad Shafi Kuchay, Nitin Kapoor
World Journal of Diabetes.2025;[Epub] CrossRef
Role of flibanserin in managing hypoactive sexual desire disorder in women: A systematic review and meta-analysis
A.B.M. Kamrul-Hasan, Mohammad Abdul Hannan, Muhammad Shah Alam, Fatema Tuz Zahura Aalpona, Lakshmi Nagendra, Shahjada Selim, Deep Dutta
Medicine.2024; 103(25): e38592. CrossRef
Teneligliptin: A potential therapeutic approach for diabetic cardiomyopathy
Ashraf Al Madhoun
World Journal of Diabetes.2024; 15(8): 1654. CrossRef
Inhibition of Oxidative Stress and Related Signaling Pathways in Neuroprotection
Maja Jazvinšćak Jembrek
Antioxidants.2024; 13(9): 1033. CrossRef
Safety and Efficacy of the Novel RNA Interference Therapies for Hypertriglyceridemia and Mixed Hyperlipidemia Management: A Systematic Review and Meta-analysis
A.B.M. Kamrul-Hasan, Deep Dutta, Lakshmi Nagendra, Sunetra Mondal, Saptarshi Bhattacharya, Sanjay Kalra
Endocrine Practice.2024; 30(11): 1103. CrossRef
Hepatobiliary effects and safety of tirzepatide: A systematic review and meta‐analysis
A. B. M. Kamrul‐Hasan, Deep Dutta, Lakshmi Nagendra, Mohammad Shafi Kuchay, Md. Saiful Islam, Joseph M. Pappachan
Diabetes, Obesity and Metabolism.2024; 26(12): 6074. CrossRef
Efficacy and Safety of Ertugliflozin Compared to Placebo in Patients With Type 2 Diabetes: An Updated Systematic Review and Meta‐Analysis
A. B. M. Kamrul-Hasan, Muhammad Shah Alam, Samir Kumar Talukder, Mohammad Abdul Hannan, Deep Dutta, Lakshmi Nagendra, Shahjada Selim, Eusebio Chiefari
Journal of Diabetes Research.2024;[Epub] CrossRef
Optimal Use of Once-Weekly Basal Insulin Efsitora Alfa in Type 1 and Type 2 Diabetes: A Systematic Review and Meta-Analysis
Deep Dutta, Lakshmi Nagendra, Manoj Kumar, A.B.M. Kamrul-Hasan, Saptarshi Bhattacharya
Endocrine Practice.2024;[Epub] CrossRef
Neuropsychiatric Effects of Tirzepatide: A Systematic Review and Meta-Analysis
A.B.M. Kamrul-Hasan, Sanja Borozan, Deep Dutta, Lakshmi Nagendra, Dina Shrestha, Joseph M. Pappachan
Endocrine Practice.2024;[Epub] CrossRef
Pancreatic Safety of Tirzepatide and Its Effects on Islet Cell Function: A Systematic Review and Meta‐Analysis
A. B. M. Kamrul‐Hasan, Sunetra Mondal, Deep Dutta, Lakshmi Nagendra, Mohammed Ruhul Kabir, Joseph M. Pappachan
Obesity Science & Practice.2024;[Epub] CrossRef

Mineral, Bone & Muscle
Real-World Safety and Effectiveness of Denosumab in Patients with Osteoporosis: A Prospective, Observational Study in South Korea: Yumie Rhee, Dong-Gune Chang, Jeonghoon Ha, Sooa Kim, Yusun Lee, Euna Jo, Jung-Min Koh; Endocrinol Metab. 2022;37(3):497-505. Published online June 3, 2022; DOI: https://doi.org/10.3803/EnM.2022.1427

9,530 View
344 Download
9 Web of Science
11 Crossref

Abstract PDF PubReader ePub

Background
The efficacy and safety of denosumab have been established in a phase 3, randomized, placebo-controlled trial in Korean postmenopausal women with osteoporosis. This postmarketing surveillance study was aimed to investigate the safety and effectiveness of denosumab in Korean real-world clinical practice.
Methods
Patients with osteoporosis who had received denosumab per the Korean approved indications in the postmarketing setting between September 2014 and September 2019 were enrolled. The primary endpoint was the incidence of adverse events (AEs) and adverse drug reactions (ADRs). The secondary endpoint was the percent change from baseline in bone mineral density (BMD) of the lumbar spine, total hip, and femoral neck.
Results
Of the 3,221 patients enrolled, 3,185 were included in the safety analysis set; 2,973 (93.3%) were female, and the mean± standard deviation (SD) age was 68.9±9.9 years. The mean±SD study period was 350.0±71.4 days. AEs, fatal AEs, and ADRs occurred in 19.3%, 0.8%, and 1.6%, respectively. The most frequent AEs, occurring in >0.5% of patients, were dizziness (0.7%), arthralgia (0.7%), back pain (0.6%), and myalgia (0.6%). Hypocalcemia occurred in 0.3% of patients. There were no cases of osteonecrosis of the jaw and atypical femoral fracture. Mean±SD percent change from baseline in BMD of the lumbar spine, total hip, and femoral neck was 7.3%±23.6%, 3.6%±31.4%, and 3.2%±10.7%, respectively.
Conclusion
The safety and effectiveness of denosumab in Korean patients with osteoporosis in this study were comparable with those in the Korean randomized controlled trial, with no new safety findings.

Citations

Citations to this article as recorded by

Long-Term Efficacy and Safety of Denosumab: Insights beyond 10 Years of Use
Jeonghoon Ha, Youn-Ju Lee, Jinyoung Kim, Chaiho Jeong, Yejee Lim, Jeongmin Lee, Ki-Hyun Baek
Endocrinology and Metabolism.2025; 40(1): 47. CrossRef
Prevalence of denosumab-induced hypocalcemia: a retrospective observational study of patients routinely monitored with ionized calcium post-injection
Anna Spångeus, Johan Rydetun, Mischa Woisetschläger
Osteoporosis International.2024; 35(1): 173. CrossRef
Cost-consequence analysis of continuous denosumab therapy for osteoporosis treatment in South Korea
Seungju Cha, Minjeong Sohn, Hyowon Yang, Eric J. Yeh, Ki-Hyun Baek, Jeonghoon Ha, Hyemin Ku
BMC Musculoskeletal Disorders.2024;[Epub] CrossRef
Denosumab and the Risk of Diabetes in Patients Treated for Osteoporosis
Huei-Kai Huang, Albert Tzu-Ming Chuang, Tzu-Chi Liao, Shih-Chieh Shao, Peter Pin-Sung Liu, Yu-Kang Tu, Edward Chia-Cheng Lai
JAMA Network Open.2024; 7(2): e2354734. CrossRef
A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for denosumab
Yue He, Rong Zhang, Huarui Shen, Yingqi Liu
Frontiers in Pharmacology.2024;[Epub] CrossRef
Denosumab in Osteoporosis: Predicting Long-Term Efficacy beyond 10 Years
Jeongmin Lee, Youn-Ju Lee, Jeonghoon Ha
Journal of Bone Metabolism.2024; 31(3): 246. CrossRef
Adverse Effects of Denosumab in Kidney Transplant Recipients: A 20-Year Retrospective Single-Center Observation Study in Central Taiwan
Tsung-Yin Tsai, Zi-Hong You, Shang-Feng Tsai, Ming-Ju Wu, Tung-Min Yu, Ya-Wen Chuang, Yung-Chieh Lin, Ya-Lian Deng, Chiann-Yi Hsu, Cheng-Hsu Chen
Transplantation Proceedings.2023; 55(4): 837. CrossRef
Persistence with Denosumab in Male Osteoporosis Patients: A Real-World, Non-Interventional Multicenter Study
Chaiho Jeong, Jeongmin Lee, Jinyoung Kim, Jeonghoon Ha, Kwanhoon Jo, Yejee Lim, Mee Kyoung Kim, Hyuk-Sang Kwon, Tae-Seo Sohn, Ki-Ho Song, Moo Il Kang, Ki-Hyun Baek
Endocrinology and Metabolism.2023; 38(2): 260. CrossRef
Effect of Denosumab on Bone Density in Postmenopausal Osteoporosis: A Comparison with and without Calcium Supplementation in Patients on Standard Diets in Korea
Chaiho Jeong, Jinyoung Kim, Jeongmin Lee, Yejee Lim, Dong-Jun Lim, Ki-Hyun Baek, Jeonghoon Ha
Journal of Clinical Medicine.2023; 12(21): 6904. CrossRef
Denosumab

Reactions Weekly.2022; 1919(1): 221. CrossRef
Denosumab, an effective osteoporosis treatment option for men
Sung Hye Kong
The Korean Journal of Internal Medicine.2022; 37(5): 947. CrossRef

Clinical Study
Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis: Deep Dutta, Anshita Agarwal, Indira Maisnam, Rajiv Singla, Deepak Khandelwal, Meha Sharma; Endocrinol Metab. 2021;36(2):374-387. Published online April 6, 2021; DOI: https://doi.org/10.3803/EnM.2020.818

9,095 View
251 Download
26 Web of Science
35 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
No meta-analysis has holistically analysed and summarised the efficacy and safety of gemigliptin in type 2 diabetes. The meta-analysis addresses this knowledge gap.
Methods
Electronic databases were searched for randomised controlled trials (RCTs) involving diabetes patients receiving gemigliptin in the intervention arm and placebo/active comparator in the control arm. The primary outcome was change in haemoglobin A1c (HbA1c). The secondary outcomes were alterations in glucose, glycaemic targets, lipids, insulin resistance, and adverse events.
Results
Data from 10 RCTs involving 1,792 patients were analysed. Four had an active control group (ACG), with metformin/dapagliflozin/sitagliptin/glimepiride as the active comparator; six had a passive control group (PCG), with placebo/rosuvastatin as controls. HbA1c reduction by gemigliptin at 24 weeks was comparable to ACG (mean difference [MD], 0.09%; 95% confidence interval [CI], –0.06 to 0.23; P=0.24; I²=0%; moderate certainty of evidence [MCE]), but superior to PCG (MD, –0.91%; 95% CI, –1.18 to –0.63); P<0.01; I²=89%; high certainty of evidence [HCE]). Gemigliptin was superior to PCG regarding achieving HbA1c <7% (12 weeks: odds ratio [OR], 5.91; 95% CI, 1.34 to 26.08; P=0.02; I²=74%; 24 weeks: OR, 4.48; 95% CI, 2.09 to 9.60; P<0.01; I²=69%; HCE). Gemigliptin was comparable to ACG regarding achieving HbA1c <7% after 24 weeks (OR, 0.92; 95% CI, 0.52 to 1.63; P=0.77; I²=66%; MCE). Adverse events were similar between the gemigliptin and control groups (risk ratio [RR], 1.06; 95% CI, 0.82 to 1.36; P=0.66; I²=35%; HCE). The gemigliptin group did not have increased hypoglycaemia (RR, 1.19; 95% CI, 0.62 to 2.28; P=0.61; I²=19%; HCE).
Conclusion
Gemigliptin has good glycaemic efficacy and is well-tolerated over 6 months of use.

Citations

Citations to this article as recorded by

Efficacy and safety of the glucagon receptor antagonist volagidemab in type‐1 diabetes: A systematic review and meta‐analysis
Deep Dutta, A. B. M. Kamrul‐Hasan, Vineet Surana, Rajiv Singla, Deepak Khandelwal, Sameer Aggarwal, Lakshmi Nagendra, Saptarshi Bhattacharya
Annals of the New York Academy of Sciences.2025; 1543(1): 94. CrossRef
Optimal Use of Once-Weekly Basal Insulin Efsitora Alfa in Type 1 and Type 2 Diabetes: A Systematic Review and Meta-Analysis
Deep Dutta, Lakshmi Nagendra, Manoj Kumar, A.B.M. Kamrul-Hasan, Saptarshi Bhattacharya
Endocrine Practice.2025; 31(4): 471. CrossRef
Efficacy and Safety of Tocilizumab in Polymyalgia Rheumatica: A Systematic Review and Meta‐Analysis
Meha Sharma, Siddharth Kumar Das, Ritin Mohindra, Deep Dutta
International Journal of Rheumatic Diseases.2025;[Epub] CrossRef
Safety of Rapid Intermittent Bolus versus Slow Continuous Infusion of Hypertonic Saline for Managing Symptomatic Severe Hyponatremia: A Systematic Review and Meta-analysis
Deep Dutta, Manoj Kumar, Ameya Joshi, Meha Sharma
Annals of African Medicine.2025; 24(2): 431. CrossRef
Hyperprolactinemia Due to Prolactinoma has an Adverse Impact on Bone Health with Predominant Impact on Trabecular Bone: A Systematic Review and Meta-Analysis
Lakshmi Nagendra, Deep Dutta, Sunetra Mondal, Nitin Kapoor, Ameya Joshi, Saptarshi Bhattacharya
Journal of Clinical Densitometry.2024; 27(1): 101453. CrossRef
Impact of early initiation of ezetimibe in patients with acute coronary syndrome: A systematic review and meta-analysis
Kunal Mahajan, Lakshmi Nagendra, Anil Dhall, Deep Dutta
European Journal of Internal Medicine.2024; 124: 99. CrossRef
Efficacy and safety of dorzagliatin, a novel glucokinase activators, in the treatment of T2DM: A meta-analysis of randomized controlled trials
Yuqian Wu, Kai Wang, Jingyang Su, Xin Liu
Medicine.2024; 103(8): e36916. CrossRef
Glucagon-Like Peptide-1 Receptor Agonists in Post-bariatric Surgery Patients: A Systematic Review and Meta-analysis
Deep Dutta, Lakshmi Nagendra, Ameya Joshi, Suryashri Krishnasamy, Meha Sharma, Naresh Parajuli
Obesity Surgery.2024; 34(5): 1653. CrossRef
Orforglipron, a novel non‐peptide oral daily glucagon‐like peptide‐1 receptor agonist as an anti‐obesity medicine: A systematic review and meta‐analysis
Deep Dutta, Lakshmi Nagendra, Beatrice Anne, Manoj Kumar, Meha Sharma, A. B. M. Kamrul‐Hasan
Obesity Science & Practice.2024;[Epub] CrossRef
Safety and tolerability of sodium-glucose cotransporter-2 inhibitors in children and young adults: a systematic review and meta-analysis
Lakshmi Nagendra, Deep Dutta, Harish Bukkasagar Girijashankar, Deepak Khandelwal, Tejal Lathia, Meha Sharma
Annals of Pediatric Endocrinology & Metabolism.2024; 29(2): 82. CrossRef
Impact of Pheochromocytoma or Paraganglioma on Bone Metabolism: A Systemic Review and Meta-analysis
Deep Dutta, Lakshmi Nagendra, Manju Chandran, Meha Sharma, Saptarshi Bhattacharya, Satinath Mukhopadhyay
Journal of Clinical Densitometry.2024; 27(3): 101501. CrossRef
Long-Term Impact on Offspring (5 to 11 Years of Age) of Metformin Use in Pregnancy in Mothers With Diabetes: A Systematic Review and Meta-Analysis
Deep Dutta, Meha Sharma, Lakshmi Nagendra, Saptarshi Bhattacharya, Ritin Mohindra, Chittaranjan S. Yajnik
Endocrine Practice.2024; 30(9): 854. CrossRef
Efficacy and Safety of Osilodrostat in Managing Cushing’s Syndrome: A Systematic Review and Meta-Analysis
Lakshmi Nagendra, Deep Dutta, Nishant Raizada, Vineet Surana, Chitra Selvan, Saptarshi Bhattacharya
Indian Journal of Endocrinology and Metabolism.2024; 28(3): 232. CrossRef
Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis
Deep Dutta, Lakshmi Nagendra, BG Harish, Meha Sharma, Ameya Joshi, Basavanagowdappa Hathur, ABM Kamrul-Hasan
Indian Journal of Endocrinology and Metabolism.2024; 28(5): 436. CrossRef
Gender differences in the management and outcomes of acute coronary syndrome in indians: A systematic review and meta-analysis
Deep Dutta, Kunal Mahajan, Lokesh Verma, Gunjan Gupta, Meha Sharma
Indian Heart Journal.2024; 76(5): 333. CrossRef
Efficacy and safety of novel dual glucokinase activator dorzagliatin in type-2 diabetes A meta-analysis
Deep Dutta, Deepak Khandelwal, Manoj Kumar, Meha Sharma
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(1): 102695. CrossRef
Efficacy and safety of novel thiazolidinedione lobeglitazone for managing type-2 diabetes a meta-analysis
Deep Dutta, Saptarshi Bhattacharya, Manoj Kumar, Priyankar K. Datta, Ritin Mohindra, Meha Sharma
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(1): 102697. CrossRef
Effects of Initial Combinations of Gemigliptin Plus Metformin Compared with Glimepiride Plus Metformin on Gut Microbiota and Glucose Regulation in Obese Patients with Type 2 Diabetes: The INTESTINE Study
Soo Lim, Minji Sohn, Jose C. Florez, Michael A. Nauck, Jiyoung Ahn
Nutrients.2023; 15(1): 248. CrossRef
Systematic review and meta-analysis of teneligliptin for treatment of type 2 diabetes
R. Pelluri, S. Kongara, V. R. Nagasubramanian, S. Mahadevan, J. Chimakurthy
Journal of Endocrinological Investigation.2023; 46(5): 855. CrossRef
Efficacy and safety of enavogliflozin versus dapagliflozin added to metformin plus gemigliptin treatment in patients with type 2 diabetes: A double-blind, randomized, comparator-active study: ENHANCE-D study
Kyung-Soo Kim, Kyung Ah Han, Tae Nyun Kim, Cheol-Young Park, Jung Hwan Park, Sang Yong Kim, Yong Hyun Kim, Kee Ho Song, Eun Seok Kang, Chul Sik Kim, Gwanpyo Koh, Jun Goo Kang, Mi Kyung Kim, Ji Min Han, Nan Hee Kim, Ji Oh Mok, Jae Hyuk Lee, Soo Lim, Sang S
Diabetes & Metabolism.2023; 49(4): 101440. CrossRef
Verapamil improves One-Year C-Peptide Levels in Recent Onset Type-1 Diabetes: A Meta-Analysis
Deep Dutta, Lakshmi Nagendra, Nishant Raizada, Saptarshi Bhattacharya, Meha Sharma
Indian Journal of Endocrinology and Metabolism.2023; 27(3): 192. CrossRef
Role of novel sodium glucose co-transporter-2 inhibitor enavogliflozin in type-2 diabetes: A systematic review and meta-analysis
Deep Dutta, B.G. Harish, Beatrice Anne, Lakshmi Nagendra
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(8): 102816. CrossRef
Semaglutide and cancer: A systematic review and meta-analysis
Lakshmi Nagendra, Harish BG, Meha Sharma, Deep Dutta
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(9): 102834. CrossRef
Efficacy and Safety of Novel Thiazolidinedione Rivoglitazone in Type-2 Diabetes a Meta-Analysis
Deep Dutta, Jyoti Kadian, Indira Maisnam, Ashok Kumar, Saptarshi Bhattacharya, Meha Sharma
Indian Journal of Endocrinology and Metabolism.2023; 27(4): 286. CrossRef
Impact of early initiation of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with acute coronary syndrome: A systematic review meta-analysis
Lakshmi Nagendra, Kunal Mahajan, Gunjan Gupta, Deep Dutta
Indian Heart Journal.2023; 75(6): 416. CrossRef
Optimal use of once weekly icodec insulin in type-2 diabetes: An updated meta-analysis of phase-2 and phase-3 randomized controlled trials
Deep Dutta, Lakshmi Nagendra, Sowrabha Bhat, Ritin Mohindra, Vineet Surana, Anoop Misra
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(10): 102877. CrossRef
Impact of Enhanced External Counter-pulsation Therapy on Glycaemic Control in People With Prediabetes and Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis
Lakshmi Nagendra, Deep Dutta, Meha Sharma, Harish Bg
touchREVIEWS in Endocrinology.2023; 19(2): 8. CrossRef
Role of Novel Glucagon-like Peptide-1 Receptor Analogue Polyethylene Glycol Loxenatide in Type 2 Diabetes: A Systematic Review and Meta-analysis
Deep Dutta, Subhankar Chatterjee, Priyankar K. Datta, Ritin Mohindra, Meha Sharma
Indian Journal of Endocrinology and Metabolism.2023; 27(5): 377. CrossRef
Efficacy and Safety of Ultra-rapid Lispro Insulin in Managing Type-1 and Type-2 Diabetes: A Systematic Review and Meta-Analysis
Deep Dutta, Lakshmi Nagendra, Saptarshi Bhattacharya, Meha Sharma
Indian Journal of Endocrinology and Metabolism.2023; 27(6): 467. CrossRef
Safety and efficacy of once weekly dipeptidyl-peptidase-4 inhibitor trelagliptin in type-2 diabetes: A meta-analysis
Deep Dutta, Ritin Mohindra, Vineet Surana, Meha Sharma
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2022; 16(4): 102469. CrossRef
Efficacy and safety of hydroxychloroquine for managing glycemia in type-2 diabetes: A systematic review and meta-analysis
D Dutta, R Jindal, D Mehta, M Kumar, M Sharma
Journal of Postgraduate Medicine.2022; 68(2): 85. CrossRef
Gemigliptin exerts protective effects against doxorubicin-induced hepatotoxicity by inhibiting apoptosis via the regulation of fibroblast growth factor 21 expression
Kyeong-Min Lee, Yeo Jin Hwang, Gwon-Soo Jung
Biochemical and Biophysical Research Communications.2022; 626: 135. CrossRef
Reporting and methodological quality of systematic reviews of DPP-4 inhibitors for patients with type 2 diabetes mellitus: an evidence-based mapping
Zouxi Du, Tingting Lu, Mingdong Gao, Limin Tian
Acta Diabetologica.2022; 59(12): 1539. CrossRef
Ranirestat Improves Electrophysiologic but not Clinical Measures of Diabetic Polyneuropathy
Deep Dutta, Ritin Mohindra, Manoj Kumar, Ashok Kumar, Meha Sharma
Indian Journal of Endocrinology and Metabolism.2022; 26(5): 399. CrossRef
Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: A Cochrane meta-analysis
Deep Dutta, Vineet Surana, Rajiv Singla, Sameer Aggarwal, Meha Sharma
Indian Journal of Endocrinology and Metabolism.2021; 25(6): 475. CrossRef

Clinical Study
Efficacy and Safety of Pitavastatin in a Real-World Setting: Observational Study Evaluating SaFety in Patient Treated with Pitavastatin in Korea (PROOF Study): In-Kyung Jeong, Sung-Rae Kim; Endocrinol Metab. 2020;35(4):882-891. Published online December 2, 2020; DOI: https://doi.org/10.3803/EnM.2020.723

9,297 View
303 Download
1 Web of Science
3 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
While randomized controlled trials provide useful information about drug safety and efficacy, they do not always reflect the observed results in the real world. The prospective, observational, non-comparative trial in South Korea was designed to evaluate the efficacy and safety of pitavastatin in clinical practice in 28,343 patients.
Methods
This study was conducted in 893 facilities in Korea from April 2, 2012 to April 1, 2017. This study was designed to administer 1, 2, or 4 mg pitavastatin to patients with hyperlipidemia at the age of 20 or older for at least 8 weeks.
Results
For 126 days of mean duration of administration of pitavastatin, the % change of low density lipoprotein cholesterol indicated a dose dependent reduction: –23.4%, –29.1%, and –35.2% in the 1, 2, and 4 mg groups, respectively in patients who have not been treated with lipid lowering medications prior to study. Only 1.74% (492/28,343) of pitavastatin-treated patients experienced adverse events, of which 0.43% (123/28,343) were adverse drug reactions. Less than 1% of patients experienced the grade 2 or more toxicity (Common Terminology Criteria for Adverse Events v4.03) in alanine aminotransferase, aspartate aminotransferase, serum creatinine, and serum creatine phosphokinase. Although there were no rhabdomyolysis in 28,343 patients, 0.04% of patients had been reported pitavastatin-related musculoskeletal disorders.
Conclusion
Overall, this observational study showed that pitavastatin was well tolerated and effectively modified the lipid profile, reducing cardiovascular and cerebrovascular risk in Korean patients with hypercholesterolemia in the real world.

Citations

Citations to this article as recorded by

Systematic Review on Efficacy, Effectiveness, and Safety of Pitavastatin in Dyslipidemia in Asia
Nam Xuan Vo, Huong Lai Pham, Tan Trong Bui, Tien Thuy Bui
Healthcare.2024; 13(1): 59. CrossRef
Polymorphic form K of Pitavastatin calcium: an advance in stability and pharmaceutical applications
Renan Marcel Bonilha Dezena
Pharmacy & Pharmacology International Journal.2024; 12(5): 191. CrossRef
Low-Density Lipoprotein Cholesterol Level, Statin Use and Myocardial Infarction Risk in Young Adults
Heekyoung Jeong, Kyungdo Han, Soon Jib Yoo, Mee Kyoung Kim
Journal of Lipid and Atherosclerosis.2022; 11(3): 288. CrossRef

Clinical Study
Revisiting Rupture of Benign Thyroid Nodules after Radiofrequency Ablation: Various Types and Imaging Features: Sae Rom Chung, Jung Hwan Baek, Jin Yong Sung, Ji Hwa Ryu, So Lyung Jung; Endocrinol Metab. 2019;34(4):415-421. Published online December 23, 2019; DOI: https://doi.org/10.3803/EnM.2019.34.4.415

8,270 View
121 Download
30 Web of Science
32 Crossref

Abstract PDF PubReader ePub

Background

To evaluate the imaging features, clinical manifestations, and prognosis of patients with thyroid nodule rupture after radiofrequency ablation (RFA).

Methods

The records of 12 patients who experienced thyroid nodule rupture after RFA at four Korean thyroid centers between March 2010 and July 2017 were retrospectively reviewed. Clinical data evaluated included baseline patient characteristics, treatment methods, initial presenting symptoms, imaging features, treatment, and prognosis.

Results

The most common symptoms of post-RFA nodule rupture were sudden neck bulging and pain. Based on imaging features, the localization of nodule rupture was classified into three types: anterior, posterolateral, and medial types. The anterior type is the most often, followed by posterolateral and medial type. Eight patients recovered completely after conservative treatment. Four patients who did not improve with conservative management required invasive procedures, including incision and drainage or aspiration.

Conclusion

Thyroid nodule rupture after RFA can be classified into three types based on its localization: anterior, posterolateral, and medial types. Because majority of thyroid nodule ruptures after RFA can be managed conservatively, familiarity with these imaging features is essential in avoiding unnecessary imaging workup or invasive procedures.

Citations

Citations to this article as recorded by

Thyroid nodule rupture after thermal ablation for benign thyroid nodules: incidence, risk factors, and clinical management
Yu-tong Liu, Ying Wei, Zhen-Long Zhao, Jie Wu, Shi-Liang Cao, Na Yu, Yan Li, Li-Li Peng, Ming-an Yu
International Journal of Hyperthermia.2025;[Epub] CrossRef
Clinical study on the relationship between the incidence of complications and tumour size after thermal ablation of benign thyroid nodules
Han-xiao Zhao, Ying Wei, Zhen-long Zhao, Li-li Peng, Yan Li, Jie Wu, Shi-liang Cao, Na Yu, Ming-an Yu
International Journal of Hyperthermia.2025;[Epub] CrossRef
Ablation therapies for thyroid nodules and parathyroid adenomas: What we should know?
Tümay Bekci, Uluhan Eryürük
CERASUS JOURNAL OF MEDICINE.2025; 2(1): 1. CrossRef
Chinese guidelines for ultrasound-guided thermal ablation of thyroid nodules (2024 edition)
Zhi-Yu Han, Jian-Ping Dou, Lin Zheng, Min Xu, Jie Ren, Hui Wang, Shu-Rong Wang, Wei-Wei Zhan, Jian-Qiao Zhou, Shu-Hang Xu, Wen Cheng, Man Lu, Dong Xu, Jie Yu, Fei Jing, Ming-an Yu, Song-Yuan Yu, Zhi-Gang Cheng, Cheng-Zhong Peng, Ying Che, Wei-de Dai, Zu-B
International Journal of Surgery.2025; 111(2): 1699. CrossRef
Assessing the efficacy of thyroid nodule radiofrequency ablation using patient-reported outcome measures
Ege Akgun, Gustavo Romero-Velez, Eren Berber
Surgery.2024; 175(3): 654. CrossRef
The Comparison of Efficacy and Safety between Radiofrequency Ablation Alone and Ethanol Ablation Followed by Radiofrequency Ablation in the Treatment of Mixed Cystic and Solid Thyroid Nodule
Min Gang Jo, Min Kyoung Lee, Jae Ho Shin, Min Guk Seo, So Lyung Jung
Journal of the Korean Society of Radiology.2024; 85(3): 618. CrossRef
Cutaneous fistula formation after thyroid nodule rupture: A rare complication after radiofrequency ablation
Amanda J. Bastien, Luv Amin, Jeffrey Moses, Wendy Sacks, Allen S. Ho
Head & Neck.2024;[Epub] CrossRef
Brazilian Consensus on the Application of Thermal Ablation for Treatment of Thyroid Nodules: A Task Force Statement by the Brazilian Society of Interventional Radiology and Endovascular Surgery (SOBRICE), Brazilian Society of Head and Neck Surgery (SBCCP)
Gustavo Philippi de los Santos, Marco Aurélio Vamondes Kulcsar, Fabio de Aquino Capelli, Jose Higino Steck, Klecius Leite Fernandes, Cleo Otaviano Mesa, Joaquim Mauricio da Motta-Leal-Filho, Rafael Selbach Scheffel, Fernanda Vaisman, Guilherme Lopes Pinhe
Archives of Endocrinology and Metabolism.2024;[Epub] CrossRef
Thyroid nodule rupture after radiofrequency ablation: case report and literature review
Tatiana Ferraro, Sameeha Sajid, Steven P. Hodak, Chelsey K. Baldwin
Frontiers in Endocrinology.2024;[Epub] CrossRef
Thyroid Nodule Rupture Following Radiofrequency Ablation for Benign Thyroid Nodules
Joaquin Austerlitz, Daljit Singh Mann, Julia E. Noel, Lisa A. Orloff
JAMA Otolaryngology–Head & Neck Surgery.2024; 150(8): 651. CrossRef
Microwave versus Radiofrequency Ablation in Treating Predominantly Solid Benign Thyroid Nodules: A Randomized Controlled Trial
Sitong Chen, Jianping Dou, Yuancheng Cang, Ying Che, Gang Dong, Chunlai Zhang, Dong Xu, Qinxian Long, Jie Yu, Ping Liang
Radiology.2024;[Epub] CrossRef
Radiofrequency Ablation for Benign Thyroid Nodules: Radiology In Training
Ningcheng Li, Timothy C. Huber
Radiology.2023; 306(1): 54. CrossRef
A Case of Thyroid Abscess Following Ethanol Ablation for Benign Thyroid Nodule
Heungrae Cho, Dongbin Ahn, Ji Hye Kwak, Gil Joon Lee
Korean Journal of Otorhinolaryngology-Head and Neck Surgery.2023; 66(9): 624. CrossRef
Radiofrequency Ablation for Benign Thyroid Nodules
Julia E Noel, Catherine F Sinclair
The Journal of Clinical Endocrinology & Metabolism.2023; 109(1): e12. CrossRef
2022 Taiwan clinical multicenter expert consensus and recommendations for thyroid radiofrequency ablation
Wei-Che Lin, Wen-Chieh Chen, Pei-Wen Wang, Yi-Chia Chan, Yen-Hsiang Chang, Harn-Shen Chen, Szu-Tah Chen, Wei-Chih Chen, Kai-Lun Cheng, Shun-Yu Chi, Pi-Ling Chiang, Chen-Kai Chou, Feng-Fu Chou, Shun-Chen Huang, Feng-Hsuan Liu, Sheng-Dean Luo, Fen-Yu Tseng,
Ultrasonography.2023; 42(3): 357. CrossRef
Effective and Safe Application of Radiofrequency Ablation for Benign Thyroid Nodules
Jin Yong Sung
Journal of the Korean Society of Radiology.2023; 84(5): 985. CrossRef
General Principles for the Safe Performance, Training, and Adoption of Ablation Techniques for Benign Thyroid Nodules: An American Thyroid Association Statement
Catherine F. Sinclair, Jung Hwan Baek, Kathleen E. Hands, Steven P. Hodak, Timothy C. Huber, Iram Hussain, Brian Hung-Hin Lang, Julia E. Noel, Maria Papaleontiou, Kepal N. Patel, Gilles Russ, Jonathon Russell, Stefano Spiezia, Jennifer H. Kuo
Thyroid®.2023; 33(10): 1150. CrossRef
Échographie de la thyroïde
H. Monpeyssen, J. Tramalloni
EMC - Endocrinologie - Nutrition.2023; 34(2): 1. CrossRef
Radiofrequency ablation and thyroid cancer: review of the current literature
Haris Muhammad, Aniqa Tehreem, Jonathon O. Russell
American Journal of Otolaryngology.2022; 43(1): 103204. CrossRef
Microwave Ablation Vs Traditional Thyroidectomy for Benign Thyroid Nodules: A Prospective, Non-Randomized Cohort Study
Shaokun Li, Mingfeng Yang, Haipeng Guo, Muyuan Liu, Shaowei Xu, Hanwei Peng
Academic Radiology.2022; 29(6): 871. CrossRef
Radiofrequency ablation and related ultrasound‐guided ablation technologies for treatment of benign and malignant thyroid disease: An international multidisciplinary consensus statement of the American Head and Neck Society Endocrine Surgery Section with
Lisa A. Orloff, Julia E. Noel, Brendan C. Stack, Marika D. Russell, Peter Angelos, Jung Hwan Baek, Kevin T. Brumund, Feng‐Yu Chiang, Mary Beth Cunnane, Louise Davies, Andrea Frasoldati, Anne Y. Feng, Laszlo Hegedüs, Ayaka J. Iwata, Emad Kandil, Jennifer K
Head & Neck.2022; 44(3): 633. CrossRef
Thyroid Nodule Radiofrequency Ablation: Complications and Clinical Follow Up
James Y. Lim, Jennifer H. Kuo
Techniques in Vascular and Interventional Radiology.2022; 25(2): 100824. CrossRef
Minimally-invasive treatments for benign thyroid nodules: recommendations for information to patients and referring physicians by the Italian Minimally-Invasive Treatments of the Thyroid group
Giovanni Mauri, Stella Bernardi, Andrea Palermo, Roberto Cesareo, Enrico Papini, Luigi Solbiati, Daniele Barbaro, Salvatore Monti, Maurilio Deandrea, Laura Fugazzola, Giovanni Gambelunghe, Roberto Negro, Stefano Spiezia, Fulvio Stacul, Luca Maria Sconfien
Endocrine.2022; 76(1): 1. CrossRef
American Association of Clinical Endocrinology Disease State Clinical Review: The Clinical Utility of Minimally Invasive Interventional Procedures in the Management of Benign and Malignant Thyroid Lesions
Sina Jasim, Kepal N. Patel, Gregory Randolph, Stephanie Adams, Roberto Cesareo, Edward Condon, Tara Henrichsen, Malak Itani, Maria Papaleontiou, Leonardo Rangel, John Schmitz, Marius N. Stan
Endocrine Practice.2022; 28(4): 433. CrossRef
Radiofrequency Ablation of Benign and Malignant Thyroid Nodules
Patrick J. Navin, Scott M. Thompson, Anil N. Kurup, Robert A. Lee, Matthew R. Callstrom, M. Regina Castro, Marius N. Stan, Brian T. Welch, John J. Schmitz
RadioGraphics.2022; 42(6): 1812. CrossRef
SFE-AFCE-SFMN 2022 consensus on the management of thyroid nodules: Thermal ablation
Adrien Ben Hamou, Edouard Ghanassia, Arnaud Muller, Miriam Ladsous, Nunzia Cinzia Paladino, Laurent Brunaud, Laurence Leenhardt, Gilles Russ
Annales d'Endocrinologie.2022; 83(6): 423. CrossRef
Complications of RFA for Thyroid Nodules: Prevention and Management
Rahul K. Sharma, Jennifer H Kuo
Current Otorhinolaryngology Reports.2021; 9(1): 79. CrossRef
Ultrasonographic characteristics of thyroid nodule rupture after microwave ablation
Peng Tian, Wenyan Du, Xiaoxi Liu, Yiwen Ding, Zekai Zhang, Jing Li, Yanzhen Wang
Medicine.2021; 100(9): e25070. CrossRef
Symptomatic aseptic necrosis of benign thyroid lesions after microwave ablation: risk factors and clinical significance
Jian-ping Dou, Jie Yu, Zhi-gang Cheng, Fang-yi Liu, Xiao-ling Yu, Qi-di Hou, Fang Liu, Zhi-yu Han, Ping Liang
International Journal of Hyperthermia.2021; 38(1): 815. CrossRef
The Importance of Nodule Size in the Management of Ruptured Thyroid Nodule After Radiofrequency Ablation: A Retrospective Study and Literature Review
Wen-Chieh Chen, Sheng-Dean Luo, Wei-Chih Chen, Chen-Kai Chou, Yen-Hsiang Chang, Kai-Lun Cheng, Wei-Che Lin
Frontiers in Endocrinology.2021;[Epub] CrossRef
Long-Term Follow-Up of Single-Fiber Multiple Low-Intensity Energy Laser Ablation Technique of Benign Thyroid Nodules
Mattia Squarcia, Mireia Mora, Gloria Aranda, Enrique Carrero, Daniel Martínez, Ramona Jerez, Ricard Valero, Joan Berenguer, Irene Halperin, Felicia A. Hanzu
Frontiers in Oncology.2021;[Epub] CrossRef
Effectiveness of Injecting Cold 5% Dextrose into Patients with Nerve Damage Symptoms during Thyroid Radiofrequency Ablation
Min Kyoung Lee, Jung Hwan Baek, Sae Rom Chung, Young Jun Choi, Yu-Mi Lee, Tae Yong Kim, Jeong Hyun Lee
Endocrinology and Metabolism.2020; 35(2): 407. CrossRef

Thyroid
A Comparison of Ultrasound-Guided Fine Needle Aspiration versus Core Needle Biopsy for Thyroid Nodules: Pain, Tolerability, and Complications: Eun Ji Jeong, Sae Rom Chung, Jung Hwan Baek, Young Jun Choi, Jae Kyun Kim, Jeong Hyun Lee; Endocrinol Metab. 2018;33(1):114-120. Published online March 21, 2018; DOI: https://doi.org/10.3803/EnM.2018.33.1.114

7,491 View
72 Download
24 Web of Science
23 Crossref

Abstract PDF PubReader ePub

Background

To compare pain, tolerability, and complications associated with fine needle aspiration (FNA) versus core needle biopsy (CNB).

Methods

FNAs were performed using 23-gauge needles and CNBs were performed using 18-gauge double-action spring-activated needles in 100 patients for each procedure. Patients were asked to record a pain score using a 10-cm visual analog scale and procedure tolerability. Complications and number of biopsies were recorded.

Results

The median pain scores were similar for the FNA and CNB approaches during and 20 minutes after the biopsy procedures (3.7 vs. 3.6, P=0.454; 0.9 vs. 1.1, P=0.296, respectively). The procedure was tolerable in all 100 FNA patients and in 97 CNB patients (P=0.246). The mean number of biopsies was fewer in the CNB group (1.4 vs. 1.2, P=0.002). By subgroup analysis (staff vs. non-staff), no significant difference was detected in any parameter. There were no major complications in either group, but three patients who underwent CNB had minor complications (P=0.246).

Conclusion

FNA and CNB show no significant differences for diagnosing thyroid nodules in terms of pain, tolerability, or complications.

Citations

Citations to this article as recorded by

A comparative analysis of core needle biopsy and repeat fine needle aspiration in patients with inconclusive initial cytology of thyroid nodules
Xuejiao Su, Can Yue, Wanting Yang, Buyun Ma
Frontiers in Endocrinology.2024;[Epub] CrossRef
Assessing Adequacy: A Meta-Analysis of Rapid Onsite Evaluation of Thyroid Nodules
Peter P. Issa, Christina McCarthy, Mohammad Hussein, Aaron L. Albuck, Essam Emad, Mohamed Shama, Krzysztof Moroz, Eman Toraih, Emad Kandil
Journal of Surgical Research.2024; 296: 523. CrossRef
Reliability of Thyroid Imaging Reporting and Data Systems' Scoring in the Evaluation of Thyroid Nodules
Zeynep Ergenç, Hasan Ergenç, Erkan Aksoy, Özlem Karaca Ocak, Kerim Güzel, Feyzi Gökosmanoğlu
Experimental and Applied Medical Science.2024; 5(3): 150. CrossRef
Histology-based and cytology-based needle sampling for targeted next-generation sequencing in the indeterminate thyroid tumors
Chun-Nan Chen, Tsung-Lin Yang
European Archives of Oto-Rhino-Laryngology.2023; 280(8): 3773. CrossRef
Preoperative evaluation of thyroid nodules – Diagnosis and management strategies
Tapoi Dana Antonia, Lambrescu Ioana Maria, Gheorghisan-Galateanu Ancuta-Augustina
Pathology - Research and Practice.2023; 246: 154516. CrossRef
Keloid Development After Fine Needle Aspiration of the Thyroid: A Rare Case and Review of Management Strategies
Shaniah S Holder, Alaerebo S Malvan-iyalla, Sara Arfan, Vimal Basani, Frederick Tiesenga
Cureus.2023;[Epub] CrossRef
Utilidad de la biopsia con aguja gruesa ecoguiada en nódulos tiroideos con punción aspirativa con aguja fina no diagnóstica
R. Cortázar-García, M.D. Martín-Escalante, L. Robles-Cabeza, C. Martínez-Santos
Radiología.2022; 64(3): 195. CrossRef
Thyroid diagnostic modalities (fine needle aspiration and core needle biopsy) with histology correlation: a tertiary centre experience
Sona J Appukutty, Anna Paterson, Nishant S Patel, Adam Duckworth, James Chan, Maria O'Donovan, Alison J Marker
Journal of Clinical Pathology.2022; 75(9): 620. CrossRef
Diagnostic performance of core needle biopsy for nodal recurrences in patients with head and neck squamous cell carcinoma
Ta-Hsuan Lo, Cheng-Ping Wang, Chun-Nan Chen, Tsung-Lin Yang, Pei-Jen Lou, Jenq-Yuh Ko, Yih-Leong Chang, Tseng-Cheng Chen
Scientific Reports.2022;[Epub] CrossRef
The efficacy of incorporating ultrasound-guided core biopsy into the clinical workflow of indeterminate thyroid tumors
Chun-Nan Chen, Min-Shu Hsieh, Yi-Hsuan Lee, Tsung-Lin Yang
Journal of the Formosan Medical Association.2022; 121(10): 2012. CrossRef
A Literature Review of Factors Associated With Pain From Fine Needle Aspiration Biopsy of Thyroid Nodules
Tao Liu, Manisha Tilak, Sara Awad, Joshua Lakoff
Endocrine Practice.2022; 28(6): 628. CrossRef
Usefulness of ultrasound-guided core biopsy in thyroid nodules with inconclusive fine-needle aspiration biopsy findings
R. Cortázar-García, M.D. Martín-Escalante, L. Robles-Cabeza, C. Martínez-Santos
Radiología (English Edition).2022; 64(3): 195. CrossRef
Permanent vocal fold paralysis after ultrasound-guided core needle biopsy of thyroid nodule
Kathrin Zimmerman, Matthew Hoffman, Amalee Smith, C. Blake Simpson
Otolaryngology Case Reports.2022; 24: 100455. CrossRef
Interobserver variability in ultrasound assessment of thyroid nodules
Jaber Alyami, Fahad F. Almutairi, Sultan Aldoassary, Amani Albeshry, Ali Almontashri, Mazen Abounassif, Majed Alamri
Medicine.2022; 101(41): e31106. CrossRef
Usage and Diagnostic Yield of Fine-Needle Aspiration Cytology and Core Needle Biopsy in Thyroid Nodules: A Systematic Review and Meta-Analysis of Literature Published by Korean Authors
Soon-Hyun Ahn
Clinical and Experimental Otorhinolaryngology.2021; 14(1): 116. CrossRef
Hydrodissection: A Novel Approach for Safe Core Needle Biopsy of Small High-Risk Subcapsular Thyroid Nodules
Hojat Ebrahiminik, Hossein Chegeni, Javad Jalili, Rambod Salouti, Hadi Rokni, Afshin Mohammadi, Ali Mosaddegh Khah, Seyed Mohammad Tavangar, Zahra Ebrahiminik
CardioVascular and Interventional Radiology.2021; 44(10): 1651. CrossRef
A Blinded Randomized Trial Comparing 2 Needle Gauges for Fine‐Needle Biopsy of Thyroid Nodules
Christopher M. Shumrick, Jonathan C. Simmonds, Lorna L. Ogden, Cindi A. Snowden, Jagdish K. Dhingra
OTO Open.2021;[Epub] CrossRef
Application of biomarkers in the diagnosis of uncertain samples of core needle biopsy of thyroid nodules
Yan Xiong, Xin Li, Li Liang, Dong Li, Limin Yan, Xueying Li, Jiting Di, Ting Li
Virchows Archiv.2021; 479(5): 961. CrossRef
Diagnostic Efficacy and Safety of Core Needle Biopsy as a First-Line Diagnostic Method for Thyroid Nodules: A Prospective Cohort Study
Min Ji Hong, Dong Gyu Na, Hunkyung Lee
Thyroid.2020; 30(8): 1141. CrossRef
Comparison Between Fine Needle Aspiration and Core Needle Biopsy for the Diagnosis of Thyroid Nodules: Effective Indications According to US Findings
Soo Yeon Hahn, Jung Hee Shin, Young Lyun Oh, Ko Woon Park, Yaeji Lim
Scientific Reports.2020;[Epub] CrossRef
2019 Practice guidelines for thyroid core needle biopsy: a report of the Clinical Practice Guidelines Development Committee of the Korean Thyroid Association
Chan Kwon Jung, Jung Hwan Baek, Dong Gyu Na, Young Lyun Oh, Ka Hee Yi, Ho-Cheol Kang
Journal of Pathology and Translational Medicine.2020; 54(1): 64. CrossRef
Pathological diagnosis of thyroid nodules based on core needle biopsies: comparative study between core needle biopsies and resected specimens in 578 cases
Yan Xiong, Limin Yan, Lin Nong, Yalin Zheng, Ting Li
Diagnostic Pathology.2019;[Epub] CrossRef
The Significance of Having an Excellent Patient's Comfort with Thyroid Core Needle Biopsy
Pierpaolo Trimboli, Luca Giovanella
Endocrinology and Metabolism.2018; 33(1): 53. CrossRef

First
Prev
Page of 1
Next
Last

Search